Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
By Adria Calatayud
Germany's Merck KGaA said it agreed to buy U.K. biotech company Silence Therapeutics for $1.3 billion, adding an experimental medicine for rare disease polycythemia vera to its drug pipeline.
Merck said Monday that it is offering $20 an American depositary share in cash for Nasdaq-listed Silence Therapeutics, more than double the target's closing price as of Friday.
The German life-sciences and chemicals group said the deal aims to strengthen its rare-disease pipeline by adding a drug candidate, divesiran, that is ready to enter late-stage clinical trials developed by Silence Therapeutics, which specializes in a gene-silencing technology called short interfering RNA.
"Following the acquisition of SpringWorks Therapeutics last year, we continue to transform our pipeline toward areas of high specialization and unmet medical need, with an ongoing commitment to external innovation," Merck Chief Executive Kai Beckmann said.
Silence Therapeutics Chairman and Interim Principal Executive Officer Iain Ross said Merck has the scale, resources and commercial capabilities to accelerate the late-stage development of the drug.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
October 19, 2026 08:44 ET (12:44 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Are TIPS ETFs the Best Way to Fight Inflation?
10 Best Blue-Chip Stocks to Buy for the Long Term
United States